PDL BioPharma Company Description
If your body starts fighting you, PDL BioPharma hopes to help you fight back. The company's antibody (protein) humanization technology makes it possible to alter mouse monoclonal antibodies (MAbs) for improved use in therapies for humans, such as preventing and treating autoimmune diseases and cancer. The firm has licensed its technology to such companies as MedImmune and Genentech for therapies including Genentech's best-selling breast-cancer treatment MAb Herceptin. The company has spun off its biotech development operations into a new company named Facet Biotech to separate them from its profit-making licensing and royalty business.
View the Comprehensive Company Description for PDL BioPharma
The Company Description provides a historical perspective of PDL BioPharma's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of PDL BioPharma's evolution in the marketplace.
